CAS号:129453-61-8
品名:氟维司群Fulvestrant
中文别名:氟维司琼;(7a,17b)-7-[9-(4,4,5,5,5-五氟戊亚磺酰基)壬烷基]-雌甾-1,3,5-(10)-三烯-3,17-二醇;
英文别名:ICI182780;ICI-182,780;(7a,17b)-7-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol;(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol;Faslodex(TradeName);
分子式:C32H47F5O3S
分子量:606.771
精确质量:606.317
Psa:76.74
RTECS号:KG7623000
MDL号:MFCD00903953
外观与性状:白色粉末
密度:1.201 g/cm3
沸点:674.8ºC at 760 mmHg
闪点:361.9ºC
折射率:1.521
储存条件:2-8ºC
蒸汽压:3.95E-19mmHg at 25°C
海关编码:2930909090
简介:Fulvestrant(tradenameFaslodex,byAstraZeneca)isadrugtreatmentofhormonereceptor-positivemetastaticbreastcancerinpostmenopausalwomenwithdiseaseprogressionfollowinganti-estrogentherapy.Itisacompleteestrogenreceptorantagonistwithnoagonisteffects,whichinaddition,acceleratestheproteasomaldegradationoftheestrogenreceptor.Thedrughaspoororalbioavailability,andisadministeredmonthlyviaintramuscularinjection.
用途:是一类新的ER抑制剂ER下调剂类乳腺癌治疗药物。可与ER竞争性结合,其亲和力可与雌二醇相比。还可阻断ER,抑制其与雌激素的结合,并激发受体发生形态改变,降低ER浓度,从而使肿瘤细胞受到损害。用于治疗晚期已经发生全身转移的乳腺癌,用于抗雌激素疗法治疗无效、雌激素受体(ER)呈阳性的绝经后转移性晚期乳腺癌治疗。